Hubei Biocause Heilen Pharmaceutical Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 403.57 million compared to CNY 239.59 million a year ago. Revenue was CNY 405.76 million compared to CNY 240.38 million a year ago.

Net income was CNY 113.04 million compared to CNY 54.4 million a year ago. Basic earnings per share from continuing operations was CNY 0.39 compared to CNY 0.19 a year ago. Diluted earnings per share from continuing operations was CNY 0.39 compared to CNY 0.19 a year ago.